Recruiting PHASE3 INTERVENTIONAL 2-arm
NCT07288398
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2 (LEVEL-2)
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertension Patients With Heart Failure With Preserved Left Ventricular Ejection Fraction
Sponsor: Tenax Therapeutics, Inc.
Conditions
Pulmonary Hypertension Associated With HFpEF
Updated 1 time since 2026 Last updated: Dec 15, 2025 Started: Dec 31, 2025 Primary completion: Jun 30, 2028 Completion: Jun 30, 2029
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE3 trial investigates Pulmonary Hypertension Associated With HFpEF and is currently actively recruiting participants. Tenax Therapeutics, Inc. leads this study, which shows 1 recorded version since 2025 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
1 version recorded Recruiting — PHASE3
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Tenax Therapeutics, Inc.
Data source: Tenax Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .